Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

Tomas Olsson

Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

The concentration of 1463 proteins were measured using the Olink Explore platform which uses Proximity Extension Assay (PEA) technology. The proteins are preselected from four Olink panels: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology, and Explore 384 Oncology. The protein concentrations are given as Olink’s relative protein quantification unit on log2 scale: Normalized Protein Expression (NPX). The NPX values were intensity normalized by Olink. Protein levels were measured in cerebrospinal fluid samples (n = 186) and plasma samples (n = 165) from persons with multiple sclerosis and healthy controls.

Citation and access

Method and outcome

Administrative information

Topic and keywords

Metadata

Version 1

Linköping University

Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

Citation and access

Creator/Principal investigator(s):

Research principal:

Data contains personal data:

Type of personal data:

Code key exists:

Sensitive personal data:

Citation:

Data access level:

Language:

Method and outcome

Population:

Time method:

Study design:

Data format/data structure:

Administrative information

Other research principals:

DOI:

Ethics Review 1:

Ethics Review 2:

Ethics Review 3:

Ethics Review 4:

Ethics Review 5:

Ethics Review 6:

Funding

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Funding agency:

Topic and keywords

CESSDA Topic Classification:

Standard för svensk indelning av forskningsämnen 2025:

Keywords:

Metadata